AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33201358 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal irinotecan 50 or 70 mg/m²
Number of subjects: 29
Study 33201438 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Number of subjects: 10355
Study 33201789 — intervention group
Group type: EXPERIMENTAL
Intervention: Subharmonic-aided pressure estimation (SHAPE) using a US contrast agent and saline infusion
Number of subjects: 0
Study 33201789 — intervention group
Group type: COMPARATOR
Intervention: Hepatic venous pressure gradient (HVPG) measurements
Number of subjects: 0
Study 33201788 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Apparent Diffusion Coefficient (ADC) values
Number of subjects: 0
Study 33201788 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate calculations of ADC
Number of subjects: 0
Study 33201924 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-sonographic index (BSI) evaluated at baseline, 6 hours, and 24 hours after the procedure.
Number of subjects: 80
Study 33201924 — intervention group
Group type: EXPERIMENTAL
Intervention: Bio-sonographic index (BSI)
Number of subjects: 80
Study 33202069 — intervention group
Group type: EXPERIMENTAL
Intervention: AQUAped questionnaire
Number of subjects: 133
Study 33203317 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviour change intervention to support memory and brain health, details on dosage and duration not available
Number of subjects: 0
Study 33203317 — intervention group
Group type: COMPARATOR
Intervention: Control group, details not specified
Number of subjects: 0
Study 33203623 — intervention group
Group type: EXPERIMENTAL
Intervention: 13C-sucrose breath test
Number of subjects: 0
Study 33203626 — intervention group
Group type: EXPERIMENTAL
Intervention: ABCC tool used during regular consultations
Number of subjects: 360
Study 33203626 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 360
Study 33203644 — intervention group
Group type: EXPERIMENTAL
Intervention: Entinostat plus Pembrolizumab
Number of subjects: 76
Study 33203644 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 76
Study 33203645 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib at 240 mg/day with cetuximab (standard dosage)
Number of subjects: 21
Study 33203645 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib at lower doses (120 mg, 160 mg, 200 mg) with cetuximab (standard dosage)
Number of subjects: 21
Study 33203645 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 21
Study 33203665 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg daily from day 1 plus nivolumab 3 mg/kg intravenously on day 15, then every 2 weeks (phase Ib)
Number of subjects: 68
Study 33203665 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg for the first 14 days (induction) then 25 mg per day plus nivolumab on the same schedule (phase II)
Number of subjects: 68
Study 33203665 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib plus nivolumab
Number of subjects: 68
Study 33203723 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway hyper-responsiveness
Number of subjects: 0
Study 33204013 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-emptive TKIs strategy based on BCR/ABL molecular monitoring
Number of subjects: 167
Study 33204013 — intervention group
Group type: COMPARATOR
Intervention: Prophylactic TKIs from historical data
Number of subjects: 167
Study 33204020 — intervention group
Group type: EXPERIMENTAL
Intervention: Achondroplasia participants
Number of subjects: 49
Study 33204020 — intervention group
Group type: COMPARATOR
Intervention: Control group (UK Biobank participants)
Number of subjects: 49
Study 33204145 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 kHz SCS
Number of subjects: 43
Study 33204764 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (once-daily)
Number of subjects: 2795
Study 33204764 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (twice-weekly)
Number of subjects: 2795
Study 33204764 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (once-weekly)
Number of subjects: 2795
Study 33204764 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2795
Study 33205032 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant therapy with bevacizumab (Group A) for cycles 3-6
Number of subjects: 142
Study 33205032 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant therapy without bevacizumab (Group B) for cycles 3-6
Number of subjects: 142
Study 33205032 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intervention based on early PET assessment
Number of subjects: 142
Study 33205058 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 0
Study 33205280 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 mg
Number of subjects: 200
Study 33205280 — intervention group
Group type: EXPERIMENTAL
Intervention: Rescue medication
Number of subjects: 200
Study 33205280 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical parameters (duration, difficulty)
Number of subjects: 200
Study 33205280 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2C8 and C9 SNPs
Number of subjects: 200
Study 33205510 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal treatment with mechanical debridement plus systemic amoxicillin/metronidazole for 7 days
Number of subjects: 66
Study 33206198 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin-A injection alongside physical therapies
Number of subjects: 953
Study 33206198 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin-A injection
Number of subjects: 953
Study 33206198 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy following botulinum toxin-A injection
Number of subjects: 953
Study 33206198 — intervention group
Group type: COMPARATOR
Intervention: Commercially-available botulinum toxin-A agents
Number of subjects: 953
Study 33206229 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemoadsorption
Number of subjects: 76
Study 33206229 — intervention group
Group type: COMPARATOR
Intervention: Control (no haemoadsorption)
Number of subjects: 76
Study 33206392 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal dexamethasone implant 0.7mg
Number of subjects: 4348
Study 33206624 — intervention group
Group type: EXPERIMENTAL
Intervention: Discover Learning Intervention (3-arm randomized controlled trial with incremental intervention components)
Number of subjects: 579
Study 33206624 — intervention group
Group type: EXPERIMENTAL
Intervention: Discover Learning content (child-friendly videos, facilitated discussions, parent-child workbook)
Number of subjects: 579
Study 33206624 — intervention group
Group type: EXPERIMENTAL
Intervention: After-school, technology-driven, experiential learning sessions
Number of subjects: 579
Study 33206936 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-genome sequencing (WGS) of paired circulating CLL (PB-CLL) and RS biopsies (tissue-RS)
Number of subjects: 17
Study 33206936 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-genome sequencing (WGS)
Number of subjects: 17
Study 33206936 — intervention group
Group type: EXPERIMENTAL
Intervention: RNA expression profiling
Number of subjects: 17
Study 33206936 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated analysis of WGS and RNA expression data
Number of subjects: 17
Study 33207004 — intervention group
Group type: EXPERIMENTAL
Intervention: Pessary
Number of subjects: 478
Study 33207004 — intervention group
Group type: COMPARATOR
Intervention: Pessary plus PFMT
Number of subjects: 478
Study 33207078 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP)
Number of subjects: 644
Study 33207078 — intervention group
Group type: EXPERIMENTAL
Intervention: Enthesitis score
Number of subjects: 644
Study 33207078 — intervention group
Group type: EXPERIMENTAL
Intervention: Bath Ankylosing Spondylitis Metrology Index
Number of subjects: 644
Study 33207078 — intervention group
Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 644
Study 33207247 — intervention group
Group type: EXPERIMENTAL
Intervention: GDF-15 neutralization with monoclonal antibody mAB1
Number of subjects: 0
Study 33207247 — intervention group
Group type: COMPARATOR
Intervention: Platinum-based chemotherapy
Number of subjects: 0
Study 33207247 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy agents with high clinical emetic score
Number of subjects: 0
Study 33207247 — intervention group
Group type: COMPARATOR
Intervention: GDF-15 knockout mice
Number of subjects: 0
Study 33207939 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 28
Study 33207939 — intervention group
Group type: COMPARATOR
Intervention: Control (no oxytocin)
Number of subjects: 28
Study 33208055 — intervention group
Group type: EXPERIMENTAL
Intervention: BRASS intervention
Number of subjects: 0
Study 33208090 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild cognitive impairment (MCI)
Number of subjects: 182
Study 33208090 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 182
Study 33208090 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of comorbidities
Number of subjects: 182
Study 33208090 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 182
Study 33208090 — intervention group
Group type: EXPERIMENTAL
Intervention: Frailty
Number of subjects: 182
Study 33208090 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life physical component summary
Number of subjects: 182
Study 33208090 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life mental component summary
Number of subjects: 182
Study 33208090 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital status
Number of subjects: 182
Study 33208090 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-income
Number of subjects: 182
Study 33208090 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent hospitalization
Number of subjects: 182
Study 33208134 — intervention group
Group type: EXPERIMENTAL
Intervention: High physical work demands and leg pain intensity ≥7 (scale 0-10)
Number of subjects: 12879
Study 33208134 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of high physical work demands and high leg pain intensity
Number of subjects: 12879
Study 33208158 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide mimetic of ADAM22 ligand LGI1 (LGI1MIM)
Number of subjects: 843
Study 33208158 — intervention group
Group type: EXPERIMENTAL
Intervention: ADAM22
Number of subjects: 843
Study 33208158 — intervention group
Group type: EXPERIMENTAL
Intervention: Global transcriptomic analysis
Number of subjects: 843
Study 33208301 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Brains-Fitbit (AB-F)
Number of subjects: 21
Study 33208301 — intervention group
Group type: COMPARATOR
Intervention: Health Enhancement Program (HEP)
Number of subjects: 21
Study 33208326 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct-acting antivirals (DAAs) treatment consisting of sofosbuvir and daclatasvir for 12 weeks, with ribavirin added in cases of cirrhosis.
Number of subjects: 1050
Study 33208914 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation (HSCT) for consolidation in s/tAML patients
Number of subjects: 644
Study 33208914 — intervention group
Group type: COMPARATOR
Intervention: Allogeneic stem cell transplantation (HSCT) for consolidation in de novo AML patients
Number of subjects: 644
Study 33209056 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine 0.1 mg/kg
Number of subjects: 75
Study 33209056 — intervention group
Group type: EXPERIMENTAL
Intervention: Serratus anterior plane block (SAPB) with 25 mL bupivacaine 0.25%
Number of subjects: 75
Study 33209056 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB) with 25 mL bupivacaine 0.25%
Number of subjects: 75
Study 33209056 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 75
Study 33209056 — intervention group
Group type: COMPARATOR
Intervention: Morphine group
Number of subjects: 75
Study 33209058 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Accelerated Radiotherapy (MARA) with concomitant boost (CB)
Number of subjects: 321
Study 33209428 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobectomy
Number of subjects: 135
Study 33209428 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcarinal lymph node dissection
Number of subjects: 135
Study 33209428 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative acid reflux
Number of subjects: 135
Study 33209428 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of anesthesia (over 153 minutes)
Number of subjects: 135
Study 33209616 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbronchial cryobiopsy (TBCB) using an ultrathin cryoprobe (1.1 mm diameter)
Number of subjects: 20
Study 33209616 — intervention group
Group type: EXPERIMENTAL
Intervention: Transbronchial cryobiopsy (TBCB) using an ultrathin cryoprobe
Number of subjects: 20
Study 33209621 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA methylation classifier
Number of subjects: 10560
Study 33209621 — intervention group
Group type: COMPARATOR
Intervention: Physician cancer probability estimates
Number of subjects: 10560
Study 33209621 — intervention group
Group type: COMPARATOR
Intervention: Validated lung nodule risk models (Mayo Clinic and Veteran's Affairs models)
Number of subjects: 10560
Study 33209626 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy combined with immunotherapy (pembrolizumab)
Number of subjects: 0
Study 33209626 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 0
Study 33209626 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive treatment strategies
Number of subjects: 0
Study 33209881 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatinib (500 mg/day)
Number of subjects: 30
Study 33210209 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic pathway including clinical risk stratification (Alvarado score), routine ultrasonography, gynecology consult for females, and selected CT after clinical reassessment.
Number of subjects: 183
Study 33210209 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic pathway
Number of subjects: 183
Study 33210217 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-administered delirium detection tools
Number of subjects: 18
Study 33210217 — intervention group
Group type: EXPERIMENTAL
Intervention: Family participation in delirium detection
Number of subjects: 18
Study 33210276 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.2 mg/day) as add-on therapy to metformin (1500-3000 mg/day) for 4 months
Number of subjects: 62
Study 33210276 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (1.2 mg/day)
Number of subjects: 62
Study 33210333 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab Q8W dosing
Number of subjects: 311
Study 33210333 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Number of subjects: 311
Study 33210445 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant
Number of subjects: 0
Study 33210445 — intervention group
Group type: EXPERIMENTAL
Intervention: PGI-S
Number of subjects: 0
Study 33210445 — intervention group
Group type: EXPERIMENTAL
Intervention: ISI
Number of subjects: 0
Study 33210466 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone scan (BS) preoperatively
Number of subjects: 691
Study 33210570 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 0
Study 33210751 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 4186
Study 33211022 — intervention group
Group type: EXPERIMENTAL
Intervention: MDA with IVM plus dihydroartemisinin-piperaquine (DP) in intervention villages
Number of subjects: 32
Study 33211022 — intervention group
Group type: COMPARATOR
Intervention: Standard malaria interventions according to the Gambian National Malaria Control Program in control villages
Number of subjects: 32
Study 33211315 — intervention group
Group type: EXPERIMENTAL
Intervention: Pimasertib (28-255 mg/day)
Number of subjects: 93
Study 33211344 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus group interviews
Number of subjects: 26
Study 33211762 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliary microbiota characterization using 16S rRNA gene sequencing and shotgun DNA sequencing.
Number of subjects: 0
Study 33211842 — intervention group
Group type: EXPERIMENTAL
Intervention: Loncastuximab tesirine (ADCT-402) at doses ranging from 15 to 200 µg/kg, with a recommended dose of 150 µg/kg every 3 weeks for 2 doses followed by 75 µg/kg every 3 weeks.
Number of subjects: 183
Study 33211907 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BtA)
Number of subjects: 313
Study 33212030 — intervention group
Group type: EXPERIMENTAL
Intervention: Dengue IgG indirect ELISA
Number of subjects: 2996
Study 33212030 — intervention group
Group type: COMPARATOR
Intervention: Focus Reduction Neutralisation Test (FRNT)
Number of subjects: 2996
Study 33212251 — intervention group
Group type: COMPARATOR
Intervention: Shipping vs local processing
Number of subjects: 1515
Study 33212251 — intervention group
Group type: COMPARATOR
Intervention: Temperature (4 °C vs ambient temperature)
Number of subjects: 1515
Study 33212251 — intervention group
Group type: COMPARATOR
Intervention: Collection tube type (heparin vs Cell Save (CS) preservation tubes)
Number of subjects: 1515
Study 33212251 — intervention group
Group type: COMPARATOR
Intervention: Treatment effect (pre- vs post-chemotherapy)
Number of subjects: 1515
Study 33212251 — intervention group
Group type: COMPARATOR
Intervention: Transit time
Number of subjects: 1515
Study 33212487 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical repair via a modified Ravitch procedure
Number of subjects: 19
Study 33212917 — intervention group
Group type: EXPERIMENTAL
Intervention: DEM-TACE using LifePearl
Number of subjects: 97
Study 33213012 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin pretreatment
Number of subjects: 70
Study 33213012 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 33213035 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,3,7-trimethylxanthine (TMX)
Number of subjects: 93
Study 33213729 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 8395
Study 33213734 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 33213734 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 0
Study 33213747 — intervention group
Group type: EXPERIMENTAL
Intervention: Evolut R/Evolut PRO
Number of subjects: 411
Study 33213747 — intervention group
Group type: COMPARATOR
Intervention: SAPIEN 3
Number of subjects: 411
Study 33213814 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ICD System
Number of subjects: 1637
Study 33213813 — intervention group
Group type: EXPERIMENTAL
Intervention: Extravascular ICD system
Number of subjects: 21
Study 33213832 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Clinical Checklist (DCC)
Number of subjects: 197
Study 33213832 — intervention group
Group type: COMPARATOR
Intervention: Paper Checklist (Control)
Number of subjects: 197
Study 33213826 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 8395
Study 33213866 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative Cognitive Dysfunction (POCD)
Number of subjects: 82
Study 33213866 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum S100B levels
Number of subjects: 82
Study 33213866 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of anesthesia
Number of subjects: 82
Study 33213866 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of Trendelenburg position
Number of subjects: 82
Study 33213866 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite Z score in tests
Number of subjects: 82
Study 33214207 — intervention group
Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnoea (OSA)
Number of subjects: 230
Study 33214207 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardised echocardiographic measurements
Number of subjects: 230
Study 33214207 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance for aortic events
Number of subjects: 230
Study 33214209 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled TD139 (0.3-10 mg, once daily for 14 days)
Number of subjects: 24
Study 33214209 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled TD139 (0.15-50 mg, single doses)
Number of subjects: 24
Study 33214209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 33214489 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotype iA (n = 47)
Number of subjects: 102
Study 33214489 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotype iB (n = 44)
Number of subjects: 102
Study 33214489 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotype iC (n = 11)
Number of subjects: 102
Study 33214615 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive interferon-α (IFN-α) treatment
Number of subjects: 68
Study 33214879 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine solution for the post-anesthesia care unit
Number of subjects: 0
Study 33215206 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative anatomical markings and surgical specimens analysis
Number of subjects: 4000
Study 33215206 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel resection length and central radicality
Number of subjects: 4000
Study 33215294 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic Patient Education (TPE) programme
Number of subjects: 0
Study 33215544 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel free-circulating and extracellular vesicle-derived miRNAs
Number of subjects: 0
Study 33215602 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporal artery thermometer (TAT)
Number of subjects: 381
Study 33215602 — intervention group
Group type: COMPARATOR
Intervention: Rectal thermometer (REC)
Number of subjects: 381
Study 33215698 — intervention group
Group type: COMPARATOR
Intervention: Medical/surgical masks
Number of subjects: 61372
Study 33215698 — intervention group
Group type: COMPARATOR
Intervention: N95/P2 respirators
Number of subjects: 61372
Study 33215698 — intervention group
Group type: COMPARATOR
Intervention: Hand hygiene
Number of subjects: 61372
Study 33215698 — intervention group
Group type: COMPARATOR
Intervention: Quarantine/physical distancing
Number of subjects: 61372